Strong Inhibition Of Insulin/IGF-1 Signaling In Early-Mid Adulthood Compresses Morbidity, But In Later Life Accelerates Aging
Scientists have long been fascinated by the insulin/IGF-1 signaling (IIS) pathway, a fundamental biological process that influences aging across many species, from tiny worms to humans. While reducing this pathway has been shown to dramatically extend lifespan in various organisms, its precise impact on “healthspan”—the duration of healthy life—has been a subject of debate.
Recent research sheds new light on this complex relationship, revealing that the timing of interventions targeting this pathway is crucial. The study found that decreasing IIS activity during early to mid-adulthood significantly extends the period of healthy life and compresses morbidity, meaning individuals spend less time experiencing age-related ailments. This is a promising finding for those seeking to not just live longer, but live healthier for longer.
However, the findings also present a surprising twist: applying the same reduction in IIS during later life actually accelerates aging. This suggests that the body’s needs change with age, and what is beneficial in youth can be detrimental in old age. In fact, the research indicates that higher levels of IIS might be more beneficial for health and survival in very elderly individuals. The study even observed that stopping the reduction of IIS in frail, elderly individuals could improve their movement and extend their lives.
These insights highlight that a universal approach to anti-aging strategies based on modulating this pathway may not be effective. Instead, future interventions might need to be tailored to specific life stages to maximize benefits and avoid unintended consequences.
Source: link to paper